Joëlle Rubert

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

Sara C. Meyer, Matthew D. Keller, Sophia Chiu et al. · Cancer Cell · 2015 · 155 citations

Medicine, Pharmacology, Pharmacotherapy +13

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

Rita Andraos, Zhiyan Qian, Débora Bonenfant et al. · Cancer Discovery · 2012 · 130 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome

Angela Mackay, Juraj Velcicky, Nina Gommermann et al. · Journal of Medicinal Chemistry · 2024 · 33 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Bim and Mcl-1 exert key roles in regulating JAK2V617Fcell survival

Joëlle Rubert, Zhiyan Qian, Rita Andraos et al. · BMC Cancer · 2011 · 25 citations · Full text

Life Sciences, Cell Biology, Hematology +14

Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis

Barbara Nuesslein‐Hildesheim, Enrico Ferrero, Cindy Schmid et al. · Journal of Neuroinflammation · 2023 · 21 citations · Full text

Life Sciences, Neurology, Pharmacology +17